Who is investing in longevity research?
This blog post has been written by the person who has mapped the longevity investment market in a clean and beautiful presentation
The longevity investment landscape exploded in 2024 with $8.49 billion in funding—a 220% year-over-year increase that caught even seasoned investors off guard.
Institutional players from pension funds to sovereign wealth funds are deploying longevity-contingent risk strategies, while venture capital firms race to back the next breakthrough in cellular reprogramming and senotherapeutics. And if you need to understand this market in 30 minutes with the latest information, you can download our quick market pitch.
Summary
The longevity investment ecosystem spans institutional risk transfer strategies worth billions and venture-backed platform technologies targeting aging pathways. The United States dominates with 84% of deal volume, while platform technologies and senotherapeutics attract the largest funding rounds.
| Investor Category | Key Players | Investment Range | Primary Focus |
|---|---|---|---|
| Institutional Investors | BT Pension Scheme, Munich Re, Swiss Re | £2.1-5B per transaction | Longevity swaps & reinsurance |
| Venture Capital | Andreessen Horowitz, Khosla Ventures | $15-250M+ rounds | Platform technologies & therapeutics |
| Family Offices | Manipal Group, Zerodha founders | $1-10M investments | Diagnostics & consumer platforms |
| Big Pharma | Pfizer, Novartis, Roche | $50-500M partnerships | Senotherapeutics & reprogramming |
| Tech Giants | Alphabet (Calico), Meta, Microsoft | $100M-3B research | AI-driven discovery platforms |
| Sovereign Wealth | Vision Fund, European pension funds | $500M-2B allocations | Late-stage platform scaling |
| Specialized Funds | The Longevity Fund, Juvenescence | $5-100M targeted rounds | Early-stage biotech & devices |
Get a Clear, Visual
Overview of This Market
We've already structured this market in a clean, concise, and up-to-date presentation. If you don't have time to waste digging around, download it now.
DOWNLOAD THE DECKWho are the biggest institutional investors actively funding longevity research today?
Pension funds lead institutional longevity investments through massive risk transfer deals worth billions per transaction.
BT Pension Scheme, Lloyds Bank Pension No. 2, and HBOS Final Salary Pension Scheme execute longevity swaps ranging from £2.1 billion to £5 billion per transaction with reinsurers like Swiss Re, RGA, and Zurich. These deals transfer longevity risk—the financial exposure to members living longer than expected—to specialized reinsurance companies.
Insurance giants Munich Re, MetLife, and Swiss Re deploy longevity reinsurance strategies to manage portfolio risk across annuities and group healthcare plans. They've developed sophisticated actuarial models to price longevity exposure and offer lifetime income solutions to pension schemes seeking to de-risk their obligations.
Asset managers like BroadRiver Asset Management, AXA IM, and UBS Wealth Management create dedicated longevity-themed investment strategies. These funds seek uncorrelated returns by investing in longevity-contingent instruments, life settlement portfolios, and thematic debt securities tied to demographic trends.
European pension de-risking surged in 2024 with record bulk annuity buy-ins projected at £70 billion, driven by rising bond yields and updated reserve requirements under Solvency II regulations.
Which notable venture capital firms have invested in longevity startups, and what companies have they backed?
Andreessen Horowitz leads venture capital engagement in longevity through strategic investments in metabolic monitoring and personalized health platforms.
| VC Firm | Notable Investments | Investment Focus |
|---|---|---|
| Andreessen Horowitz | Levels (metabolic monitoring), Thorne HealthTech (personalized supplements) | Consumer health platforms with data-driven personalization |
| Khosla Ventures | Modern Age (aging biomarkers), BioAge Labs (senotherapeutics), ŌURA | Clinical-grade biomarker platforms and therapeutic interventions |
| General Catalyst | Function Health (prevention platform), Loyal (veterinary longevity) | Preventive care platforms and cross-species longevity research |
| Apollo Health Ventures | Multiple healthspan extension startups | European-focused healthspan and wellness technology |
| Juvenescence VC | Series A epigenetic reprogramming companies | Cellular rejuvenation and regenerative medicine platforms |
| The Longevity Fund | First clinical candidates for age-related diseases since 2011 | Pioneer fund backing early-stage longevity biotech |
| Longevitytech.fund | European seed-stage biotech and diagnostics | European longevity ecosystem development |
If you want fresh and clear data on this market, you can download our latest market pitch deck here
What are the exact amounts invested or raised by top longevity-focused startups in 2024 and so far in 2025?
Total longevity investment reached $8.49 billion across 331 deals in 2024, with Q1 2025 already capturing $3.74 billion in continued momentum.
Rubedo Life Sciences led 2024 mega-rounds with a Series C exceeding $250 million for senotherapeutics development. Loyal raised $150 million in Series B funding from General Catalyst and Andreessen Horowitz for veterinary longevity biotech that translates to human applications.
ŌURA secured $200 million in Series D funding led by Khosla Ventures and GV for wearable health monitoring technology. Function Health raised $53 million in Series A from General Catalyst for personalized prevention platforms that analyze hundreds of biomarkers.
Biopeak raised $3 million in seed funding from Claypond Capital (Manipal Family Office) and Nikhil Kamath in early 2025. Rejuvenation Technologies completed a $6 million Series B round led by The Longevity Fund with angel syndicate participation.
The 2025 funding run-rate suggests annual investment could exceed $15 billion, driven by platform technology maturation and increasing institutional participation in later-stage rounds.
Which family offices, billionaires, or high-net-worth individuals are putting money into longevity research, and how much have they contributed?
Family offices and high-net-worth individuals contribute through targeted investments in diagnostic platforms and personalized health optimization services.
Manipal Group Family Office invested $3 million in Biopeak's 2025 seed round, focusing on AI-driven diagnostics and cellular therapies. Nikhil Kamath, co-founder of Zerodha, contributed $1.43 million as an angel investor to Biopeak in 2024, targeting concierge longevity clinics.
Deepinder Goyal, founder of Zomato, launched "Continue" performance venture in 2024 to back health optimization platforms. Silicon Valley biotech billionaires previously invested $3 billion in Altos Labs' 2022 funding round for epigenetic reprogramming research.
These family office investments typically range from $1-10 million per deal, targeting early-stage companies with clear commercial applications in personalized medicine and consumer health platforms.
Need a clear, elegant overview of a market? Browse our structured slide decks for a quick, visual deep dive.
What pharmaceutical or biotech giants have entered the longevity space, and through which partnerships, acquisitions, or internal ventures?
Major pharmaceutical companies establish longevity divisions through internal R&D programs, strategic acquisitions, and platform partnerships targeting aging pathways.
Pfizer announced an internal longevity R&D division in 2024 focusing on senescence and metabolic aging pathways. Novartis acquired a senotherapeutics startup in 2025 to develop in-house senolytic programs targeting cellular aging mechanisms.
Roche partnered with reprogramming biotech companies in 2025 for partial cellular reprogramming platforms. Calico, Alphabet's longevity subsidiary, collaborates with National Institutes on aging biomarkers using AI-driven target discovery.
These pharmaceutical giants typically invest $50-500 million per partnership or acquisition, seeking validated platforms with clear regulatory pathways to complement existing drug development capabilities.
The Market Pitch
Without the Noise
We have prepared a clean, beautiful and structured summary of this market, ideal if you want to get smart fast, or present it clearly.
DOWNLOADWhat kinds of technologies, therapies, or scientific breakthroughs are attracting the most funding in the longevity sector?
Longevity discovery platforms captured $2.65 billion in 2024 funding—the largest single category—by accelerating target identification and drug repurposing for age-related diseases.
Senotherapeutics attracts significant investment for senescent cell clearance technologies that remove damaged cells contributing to aging. Partial cellular reprogramming receives funding for epigenetic Yamanaka factor delivery systems that rejuvenate cells without causing cancer.
Immunosenescence and inflammation modulation programs develop high-payload antibodies and small-molecule therapies targeting chronic inflammation. Consumer longevity applications encompass wearables, digital platforms, and personalized prevention tools for metabolic health optimization.
Platform technologies receive the highest valuations because they can address multiple aging pathways simultaneously and generate recurring revenue through subscription models and ongoing therapeutic development.
If you want to build or invest on this market, you can download our latest market pitch deck here
Which countries or regions are seeing the most longevity-focused investment activity and startup formation?
The United States dominates longevity investment with 84% of global deal volume, concentrated in San Francisco Bay Area and Boston-Cambridge biotech hubs.
Europe accounts for approximately 10% of deal volume, with London, Zurich, and Germany leading regional activity. Asia captures roughly 6% of investments, with Singapore, Bengaluru, and Tel Aviv emerging as early-stage innovation centers.
India's Biopeak in Bengaluru represents growing Asian participation in longevity diagnostics. Singapore and Israel serve as bridge markets connecting European institutional capital with Asian innovation ecosystems.
Geographic concentration reflects proximity to research institutions, regulatory expertise, and established biotech investment infrastructure required for complex longevity technologies.
Who are the top-funded longevity startups right now, what do they do, and who are their investors?
Altos Labs leads funding with $3 billion raised from Vision Fund and GV for epigenetic reprogramming research targeting cellular rejuvenation.
| Startup | Technology Focus | 2024 Funding | Lead Investors |
|---|---|---|---|
| Altos Labs | Epigenetic reprogramming for cellular rejuvenation | $3B (2022 round) | Vision Fund, GV |
| BioAge Labs | Senotherapeutics targeting aging pathways | $150M Series C | Khosla, Deerfield |
| Jupiter Neurosciences | Neuroregeneration therapies | $100M Series B | General Catalyst |
| Function Health | Personalized prevention platform with 100+ biomarkers | $53M Series A | General Catalyst |
| ŌURA | Wearable health monitoring and sleep optimization | $200M Series D | Khosla Ventures, GV |
| Loyal | Veterinary longevity biotech for companion animals | $150M Series B | General Catalyst, a16z |
| Rubedo Life Sciences | Senolytic therapies for cellular aging | $250M+ Series C | Mixed VC consortium |
What are the typical deal sizes, funding stages, and terms being offered to longevity startups in recent rounds?
Longevity startup funding follows biotech patterns with extended timelines and higher capital requirements for clinical validation.
Seed and pre-seed rounds range from $0.5-5 million, focusing on proof-of-concept studies and biomarker validation. Series A and B rounds span $15-100 million for platform development and IND-enabling studies required for regulatory approval.
Later-stage venture and growth rounds exceed $100-250 million to support Phase I/II clinical trials and commercial expansion. Term structures typically include 8-year investment horizons, 20-30% ownership dilution, and mixed liquidation preferences.
Longevity deals often include milestone-based funding releases tied to clinical endpoints, regulatory approvals, and partnership achievements with pharmaceutical companies.
Wondering who's shaping this fast-moving industry? Our slides map out the top players and challengers in seconds.
We've Already Mapped This Market
From key figures to models and players, everything's already in one structured and beautiful deck, ready to download.
DOWNLOAD
If you need to-the-point data on this market, you can download our latest market pitch deck here
Which academic labs or research institutions are receiving private investment for aging-related R&D?
Harvard Center for BioRejuvenation receives private investment from Third Rock and Khosla Ventures through platform licensing and joint development agreements.
Stanford Center on Longevity partners with Manulife and APG Asset Management for innovation challenge partnerships. Indian Institute of Science (IISc) collaborates with the Longevity India forum and Biopeak for clinical validation of AI diagnostics.
These academic partnerships typically involve $5-50 million investments over 3-5 year periods, combining research grants with exclusive licensing options for commercial development.
Private investors target academic labs with validated research platforms, established intellectual property portfolios, and clear pathways to commercial applications.
How much total investment went into the longevity sector globally in 2024, and what are the forecasts for 2025 and 2026?
Global longevity investment reached $8.49 billion across 331 deals in 2024, representing a 220% year-over-year increase from previous funding levels.
2025 forecasts target continued growth exceeding $10 billion based on Q1 2025 raising $3.74 billion, indicating a $15+ billion annual run-rate. Platform technology maturation and increased institutional participation drive this acceleration.
2026 outlook suggests investments may exceed $20 billion as platform companies reach Phase II/III clinical catalysts and later-stage venture and corporate venture deployments increase. Geographic expansion beyond US markets and regulatory approval milestones will influence actual funding levels.
This growth trajectory positions longevity as a multi-billion-dollar frontier in biomedicine and AgeTech, transitioning from early-stage speculation to mature, capital-intensive execution.
Are there signs of growing interest from generalist tech investors or AI-focused funds in the longevity space?
Generalist tech investors increasingly allocate capital to longevity platform technologies that leverage AI and data analytics for drug discovery and personalized health applications.
Andreessen Horowitz and Sequoia Capital expand longevity allocations beyond traditional biotech investments. GV and Insight Partners participate in DNA-based and AI drug discovery rounds targeting aging pathways.
SoftBank Vision Fund explores large-scale epigenetics and regenerative medicine investments exceeding $500 million per deal. These tech-focused funds bring software-style scaling expectations to longevity platforms with recurring revenue models.
AI-focused funds target companies using machine learning for biomarker identification, drug repurposing, and personalized intervention protocols that can scale beyond traditional pharmaceutical development timelines.
Looking for the latest market trends? We break them down in sharp, digestible presentations you can skim or share.
Conclusion
The longevity investment ecosystem has matured from speculative early-stage funding to institutional-grade capital deployment across risk transfer strategies, platform technologies, and therapeutic development.
With $8.49 billion invested in 2024 and accelerating 2025 momentum, entrepreneurs and investors entering this market can target institutional longevity swaps, venture-backed platform technologies, or specialized therapeutic development depending on their capital requirements and risk tolerance.
Sources
- PR Newswire - Longevity Investment Report 2024
- Artemis - Longevity Swaps and Risk Transfers
- Munich Re - Business News 2024
- MetLife - Longevity Reinsurance Solutions
- BroadRiver Capital - Longevity Investment Strategy
- UniCredit - Longevity Economic Forum 2025
- Carey Olsen - Pension Funds Hedging Longevity Risk
- The Longevity Fund
- Forbes - Venture Capital Giants in Longevity
- LongevityFind - Global Longevity Industry Q2 2025
- Economic Times - Biopeak Funding News
- Exa.ai - Longevity Healthcare Startup Funding 2025
- World Economic Forum - Longevity Economy Startups